ZyGEM Teams with TATAA Biocenter
News May 04, 2012
ZyGEM Corp. Ltd. has announced that it has entered into a non-exclusive agreement with TATAA Biocenter for distribution of ZyGEM’s DNA and RNA extraction products in Sweden and other selected countries worldwide.
TAATA Biocenter is a leading provider of quantitative real-time PCR (qPCR) services and products.
This new agreement is the latest in a series of distribution agreements for ZyGEM’s DNA and RNA extraction kits with life science distributors globally.
ZyGEM’s line of nucleic acid extraction kits feature optimized formulations of proprietary enzymatic technologies that use a single-tube process to provide complete extraction of high quality DNA or RNA from specific sample types rapidly and cost effectively.
Its prepGEM™, forensicGEM™, livestockGEM™ and RNAGEM™ family of products enables nucleic acid extraction from diverse sample types for human and animal DNA and RNA testing.
“We are very pleased to be partnering with qPCR pioneer TATAA Biocenter to expand the availability of our DNA and RNA extraction products,” said Paul Kinnon, CEO of ZyGEM.
Kinnon added, “TATAA is synonymous with excellence in qPCR, and this agreement is another example of our strategy of working with diverse partners to bring the advantages of our nucleic acid extraction technologies to researchers worldwide.”
Founded in 2001 by pioneers in quantitative PCR, TATAA Biocenter is Europe's leading provider of gene expression profiling services and a prime organizer of training in qPCR and other molecular techniques to quantify nucleic acids.
Its offerings encompass the entire field of qPCR, including commissioned services and research projects, hands-on training and provision of the highest quality products.
Dr. Mikael Kubista, CEO of TATAA Biocenter, commented, “As the premier provider of qPCR services and products, we are pleased to add ZyGEM’s rapid, accurate, and easy-to-use DNA and RNA extraction kits to the select group of high quality products we make available to our customers.”
ZyGEM’s technology significantly reduces the time and cost of DNA and RNA extractions while simplifying laboratory workflow, minimizing error, reducing the risk of contamination, ensuring sample integrity and facilitating extractions from trace samples.
It is easily adaptable for use with off-the-shelf laboratory automation systems and can be specifically formulated for use with a wide range of different sample types without the need for further purification.
ZyGEM’s kits have been validated for use in highly regulated applications.
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE